Brookline Capital Acquisition (BCAC) Short Interest Ratio & Short Volume

Short interest is the volume of Brookline Capital Acquisition shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 6,800 shares of BCAC short. 0.11% of Brookline Capital Acquisition's shares are currently sold short. Learn More on Brookline Capital Acquisition's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.11% of Brookline Capital Acquisition's floating shares are currently sold short.

Brookline Capital Acquisition saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 6,800 shares, a decline of 8.1% from the previous total of 7,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Brookline Capital Acquisition currently has issued a total of 6,746,000 shares. Some of Brookline Capital Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Brookline Capital Acquisition currently has a public float of 6,180,000 shares.

0.11% of Brookline Capital Acquisition's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Brookline Capital Acquisition: Adaptimmune Therapeutics plc (2.05%), TScan Therapeutics, Inc. (4.21%), Elutia Inc. (0.34%), Genenta Science S.p.A. (0.02%), Jasper Therapeutics, Inc. (15.07%), Caribou Biosciences, Inc. (11.73%), Adverum Biotechnologies, Inc. (10.27%), Invivyd, Inc. (9.23%), Agenus Inc. (16.76%), Achilles Therapeutics plc (1.26%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.50 billion), KLA Co. ($2.53 billion), Lucid Group, Inc. ($2.50 billion), T. Rowe Price Group, Inc. ($1.91 billion), Williams-Sonoma, Inc. ($1.78 billion), Coinbase Global, Inc. ($1.78 billion), HP Inc. ($1.75 billion), Rivian Automotive, Inc. ($1.70 billion), Lumen Technologies, Inc. ($1.58 billion), and Chesapeake Energy Co. ($1.45 billion). View all of the most shorted stocks.

Short selling BCAC is an investing strategy that aims to generate trading profit from Brookline Capital Acquisition as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Brookline Capital Acquisition occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BCAC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCAC, twice per month. The most recent reporting period available is July, 15 2022.